参麦注射液治疗急性脑梗死的临床效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (573 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the therapeutic effect of Shenmai Injection on acute cerebral infarction. Methods Retrospective analysis was performed on the clinical data of 122 patients with acute cerebral infarction who were treated in the first area of the Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine from June 2017 to June 2019. According to the treatment methods, the patients were divided into treatment group (66 cases) and control group (56 cases). Both groups were given conventional treatment such as antiplatelet, lipid-lowering, hypotensive, and glycemic control, while the treatment group was given intravenous infusion of Shenmai Injection on the basis of conventional treatment. The control group was given Danhong Injection intravenously, and both groups were treated for 14 days. National Institutes of health stroke scale (NIHSS) scores and the incidence of adverse events were compared between the two groups before and after 14 days of treatment. Results After 14 days of treatment, the NIHSS scores in both groups were lower than that before treatment, and the treatment group were lower than the control group, with statistical significance (P ＜ 0.05). There was no significant difference in unknown etiology (UE) subtype NIHSS scores between the two groups before and after treatment (P ＞ 0.05). After 14 days of treatment, NIHSS scores of cardioembolism (CS), large-artery atherosclerosis (LAA), penetrating artery disease (PAD) and other etiology (OE) subtypes in both groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). The NIHSS score of LAA subtype in the treatment group was lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the NIHSS scores of CS, PAD, OE and UE subtypes between the two groups (P ＞ 0.05). No obvious adverse reactions were found in both groups during the treatment. Conclusion Shenmai Injection can effectively improve the degree of neurological impairment in patients with acute cerebral infarction, and its effect on LAA subtype cerebral infarction is obviously better than that of Danhong Injection, and its effect is similar to that of Danhong Injection in other subtypes.

Key words： Shenmai Injection Acute cerebral infarction Chinese ischemic stroke subclassification Neurological impairment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Zijun YANG Baolin YANG Junxing LYU Jingmin ZHANG Hua MA Dayong GAO Ying WEI Jingpei

Cite this article:

ZHAO Zijun YANG Baolin YANG Junxing LYU Jingmin ZHANG Hua MA Dayong GAO Ying WEI Jingpei. Clinical effect of Shenmai Injection in the treatment of acute cerebral infarction[J]. 中国医药导报, 2021, 18(20): 62-65.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I20/62

[1] 肖桂荣，王赵伟，朱仁洋，等.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国神经免疫学和神经病学杂志，2016，23（1）：51-54.
[2] 明·秦景明.症因脉治[M].上海：上海科学技术出版社，1990.
[3] 王鹂，曾萍，余青.参麦注射液在危重症中的应用及现代研究进展[J].中外医学研究，2020，18（4）：185-188.
[4] Gao S，Wang YJ，Xu AD，et al. Chinese ischemic stroke subclassification [J]. Front Neurol，2011，2：6.
[5] 中华神经学会.各类脑血管病诊断要点[J].中华神经科杂志，1996，29（6）：379-381.
[6] 侯东哲，张颖，巫嘉陵，等.中文版美国国立卫生院脑卒中量表的信度与效度研究[J].中华物理医学与康复杂志，2012，34（5）：372-374.
[7] 中国中西医结合学会神经科专业委员会.中国脑梗死中西医结合诊治指南（2017）[J].中国中西医结合杂志，2018， 38（2）：136-144.
[8] 中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9），666-682.
[9] 李佳佳，马征.TOAST分型与急性脑梗死患者近期预后的关系[J].实用临床医药杂志，2018，22（1）：58-60.
[10] Adams HP Jr，Bendixen BH，Kappelle LJ，et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST .Trial of org 10172 in acute stroke treatment [J]. Stroke，1993，24（1）：35-41.
[11] 王源，潘旭东.缺血性卒中不同亚型的血浆标志物研究进展[J].中国卒中杂志，2016，11（12）：1078-1085.
[12] 秦秀德，王家传，蔡浩斌.丹红注射液治疗缺血性脑卒中的研究进展[J].中西医结合心脑血管病杂志，2020， 18（3）：452-456.
[13] 王洪图.内经讲义[M].北京：人民卫生出版社，2002：67.
[14] 吴普.神农本草经[M].北京：人民卫生出版社，1963.
[15] 高学敏.中药学[M].北京：中国中医药出版社，2005.
[16] 赵振彪，王辉，刘歌，等.麦冬药性与功用考证[J].中医药导报，2019，25（5）：82-85.
[17] 张进进，邸莎，吉红玉，等.人参的临床应用及其用量探究[J].吉林中医药，2019，39（12）：1587-1589，1593.
[18] 韩晗，张智华，曹秋实.麦冬药对配伍探赜[J].辽宁中医药大学学报，2020，22（6）：122-125.
[19] 王若柳，王海强，范骁辉，等.LC-Q-TOF-MS和LC-IT-MS分析参麦注射液中化学成分[J].中国中药杂志，2020， 45（3）：555-564.
[20] 陈宏辉.参麦注射液化学成分分析[D].长春：吉林大学，2019.
[21] 李贵明，李燕.人参皂苷药理作用研究现状[J].中国临床药理学杂志，2020，36（8）：1024-1027.
[22] 孔令提，宋春丽，石庆平.人参皂苷对脑缺血再灌注损伤的保护机制研究现状[J].中国药房，2019，30（17）：2445-2448.
[23] 王雷雷，戴勤学.人参皂苷Rb1对脑缺血再灌注损伤小鼠LncRNA Malat1表达的调控作用[J].中国现代医生，2020，58（23）：41-44，49，193.
[24] Cheng Z，Zhang M，Ling C，et al. Neuroprotective Effects of Ginsenosides against Cerebral Ischemia [J]. Molecules，2019，24（6）：1102.
[25] Xie W，Zhou P，Sun Y，et al. Protective Effects and Target Network Analysis of Ginsenoside Rg1 in Cerebral Ischemia and Reperfusion Injury：A Comprehensive Overview of Experimental Studies [J]. Cells，2018，7（12）：270.
[26] 彭婉，马骁，王建，等.麦冬化学成分及药理作用研究进展[J].中草药，2018，49（2）：477-488.
[27] Liu H，Wang Y，Wang T，et al. De novo assembly and annotation of the Zhe-Maidong （Ophiopogon japonicus（L.f.）Ker-Gawl）transcriptome in different growth stages [J]. Sci Rep，2017，7（1）：3616.